Skip to content

Proof of concept study to investigate bioavailability of two different Curcumin formulations in healthy subjects: a randomized, controlled, cross-over study

Proof of concept study to investigate bioavailability of two different Curcumin formulations in healthy subjects: a randomized, controlled, cross-over study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00026962
Enrollment
6
Registered
2021-10-20
Start date
2021-10-22
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Group 1: Water bound curcumin, oral, 400 mg/day, single dose Group 2: Curcumin extract, oral, 400 mg/day, single dose

Sponsors

Unternehmen zur Herstellung und Vertrieb von Nahrungsergänzungsmitteln
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: - Healthy men and women - BMI: 19 - 30 kg/m2 - Non-smoker - Written consent to participate in the study - Able and willing to follow the study procedure

Exclusion criteria

Exclusion criteria: Main exclusion criteria: - Relevant history or presence of any severe medical disorder, potentially interfering with this study - Known allergy and hypersensitivity to ingredients of the study product - Blood donation within 1 month prior to study start or during study - Significant changes in lifestyle or medication (within last 3 months) or surgical intervention or surgical procedure such as bariatric surgery - For this study clinically relevant abnormal laboratory, vital signs or physical findings at screening - “Extreme dietary regimes”: vegan lifestyle, weight loss diet with <1200 kcal/day for women and <1800 kcal for men - Regular intake of drugs or supplements possibly interfering with this study within 2 weeks prior to study start or during the study (e.g. curcumin) - Chronic intake of substances affecting blood coagulation, which in the investigator’s opinion would impact subject safety - Subjects with history of drug, alcohol or other substance abuse, or other factors limiting their ability to co-operate during the study. - Known pregnancy, breast feeding or intention to become pregnant during the study. - Anticipating any planned changes in lifestyle for the duration of the study

Design outcomes

Primary

MeasureTime frame
From concentration-time curve of total curcuminoids over a time period of 0-8h the area under the curve will be determined. Comparison of AUC between study products.

Secondary

MeasureTime frame
Comparison of Cmax and Tmax between study products.

Countries

Germany

Contacts

Public ContactKatharina Knaub

BioTeSys GmbH

curcumin@biotesys.de+49-711-351 38 35

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026